BNP And NTproBNP Market Report 2026

BNP And NTproBNP Market Overview

• BNP And NTproBNP market size has reached to $2.26 billion in 2025 • Expected to grow to $4.03 billion in 2030 at a compound annual growth rate (CAGR) of 12.3% • Growth Driver: Aging Population Drives BNP and NTproBNP Market Growth • Market Trend: Rapid Screening Bioassays Shaping The BNP and NTproBNP Market Landscape • Asia-Pacific was the largest region in 2025 and North America is the fastest growing region.

The key promising market opportunities in the bnp and ntprobnp market include: • Point Of Care Testing (Segmentation By Location Of Testing) → Expected gain of $1125.87 Million • NT-proBNP (N-terminal Pro–B-Type Natriuretic Peptide) (Segmentation By Type) → Expected gain of $971.46 Million • BNP (Brain Natriuretic Peptide) (Segmentation By Type) → Expected gain of $659.88 Million

What Is Covered Under BNP And NTproBNP Market?

A BNP (B-type natriuretic peptide) and NT-proBNP (N-terminal Pro-brain Natriuretic Peptide) tests refer to a test that measures the amount of BNP or its prohormone NT-proBNP in the bloodstream, detecting heart failure and other heart-related ailments. BNP, or NT-proBNP, are natriuretic peptides that play a crucial role in regulating circulation. The high levels of BNP or NT-proBNP are indications of underlying heart disease (abnormality in pumping blood). The main types of BNP and NTproBNP are BNP (brain natriuretic peptide) and NT-proBNP (N-terminal pro-B-type natriuretic peptide). A BNP (B-type natriuretic peptide) test refers to a test that measures the amount of BNP in the bloodstream, detecting heart failure and other heart-related ailments. The location of testing includes point-of-care testing and laboratory testing for myocardial infarction, congestive heart failure, acute coronary syndrome (ACS), and others.

What Is The BNP And NTproBNP Market Growth Forecast?

The bnp and ntprobnp market size is expected to see rapid growth in the next few years. It will grow to $4.03 billion in 2030 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to increasing demand for rapid cardiac diagnostics, expansion of point-of-care testing adoption, growing elderly population base, rising integration of ai-assisted diagnostic interpretation, increasing focus on preventive cardiology care. Major trends in the forecast period include increasing adoption of high-sensitivity cardiac biomarker assays, rising use of point-of-care bnp testing devices, growing integration of automated laboratory diagnostics, expansion of early heart failure screening programs, enhanced focus on rapid turnaround diagnostic testing.

What Is The Driver Of The BNP And NTproBNP Market?

The rising geriatric population is expected to propel the growth of the BNP and NT-proBNP market going forward. The geriatric population is the segment of the population that consists of older adults, typically defined as individuals who are 65 or older. BNP and NT-proBNP serve as critical biomarkers in the geriatric population, aiding in the diagnosis and management of heart failure by providing valuable insights into cardiac function and helping guide appropriate treatment strategies for elderly individuals. For instance, in October 2025, according to the World Health Organization, a US-based specialized health agency, globally, 1 in 6 individuals will be 60 or older by 2030 and is expected to reach 2.1 billion elderly people by 2050. Therefore, the rising geriatric population is driving the growth of the BNP and NT-proBNP market.

How Will The Drivers Impact Growth In The Global BNP And NTproBNP Market?

• Rising Prevalence Of Cardiovascular Disorders (High) – During the forecast period, rising prevalence of cardiovascular disorders is expected to propel growth in the BNP and NT-proBNP market. Cardiovascular disorders are a group of conditions that affect the heart and blood vessels, including heart failure, coronary artery disease, arrhythmias and hypertension, often leading to impaired blood flow and cardiac function. Their prevalence is increasing mainly due to the single major factor of rising lifestyle-related risks such as obesity and physical inactivity, which significantly elevate heart disease incidence. BNP and NT-proBNP biomarkers support cardiovascular disorder management by enabling early detection and risk stratification of heart failure through measurable peptide levels in blood. This creates a direct clinical link between cardiovascular disease burden and the growing use of BNP and NT-proBNP diagnostic testing. Rising prevalence of cardiovascular disorders may drive the growth of the BNP and NT-proBNP market. The rising prevalence of cardiovascular disorders growth contribution during the forecast period in 2025 is 2.0%. • Rising Aging Population (Medium) – During the forecast period, a rising aging population is expected to propel growth in the BNP and NT-proBNP market. The aging population is increasing due to longer life expectancy and improved survival from chronic diseases, which raises the number of elderly individuals at risk of cardiovascular disorders. Older adults show a higher prevalence of heart failure and related cardiac stress conditions, driving demand for routine cardiac assessment. BNP and NT-proBNP testing supports the aging population by enabling early detection and risk stratification of heart failure through simple blood-based biomarkers. This helps clinicians make faster treatment decisions and manage cardiac risk more effectively in elderly patients. For instance, in October 2025, according to the World Health Organization (WHO), a Switzerland-based United Nations agency, by 2050, the global population aged 60 years and above is projected to double, reaching about 2.1 billion people. A rising aging population may drive the growth of the BNP and NT-proBNP market. The rising aging population growth contribution during the forecast period in 2025 is 1.5%. • Increasing Adoption Of Point-Of-Care Cardiac Testing (Low) – During the forecast period, increasing adoption of point-of-care cardiac testing is expected to propel growth in the BNP and NT-proBNP market. Point-of-care cardiac testing refers to rapid diagnostic testing performed near the patient, such as in emergency rooms, clinics, or ambulances, to quickly assess cardiac biomarkers and heart function without relying on centralized laboratories. It is increasing due to the growing need for faster clinical decisions, rising cardiovascular cases and expansion of portable diagnostic devices across acute care and outpatient settings. BNP and NT-proBNP tests strongly support point-of-care cardiac testing by enabling quick detection and risk stratification of heart failure at bedside. Their fast turnaround time and high clinical relevance help clinicians initiate timely treatment and improve patient triage and monitoring. Increasing adoption of point-of-care cardiac testing may drive the growth of the BNP and NT-proBNP market. The increasing adoption of point-of-care cardiac testing growth contribution during the forecast period in 2025 is 0.7%. • Increasing Emergency Department Utilization (Low) – During the forecast period, increasing emergency department utilization is expected to propel growth in the BNP and NT-proBNP market. Emergency department utilization refers to the frequency and volume of patient visits to hospital emergency departments for immediate evaluation and treatment of acute or life-threatening conditions. It is increasing mainly due to the rising burden of cardiovascular diseases and aging populations, which lead to more sudden symptom-driven hospital visits. BNP and NT-proBNP testing supports emergency department utilization by enabling rapid rule-in or rule-out of heart failure in patients presenting with shortness of breath or chest symptoms. This helps clinicians triage faster, reduce diagnostic uncertainty and make quicker admission or discharge decisions. Increasing emergency department utilization may drive the growth of the BNP and NT-proBNP market. The increasing emergency department utilization growth contribution during the forecast period in 2025 is 0.3%.

How Will The Restraints Impact Growth In The Global BNP And NTproBNP Market?

• Reimbursement Challenges (High) – During the forecast period, reimbursement challenges are restricting the growth of the BNP and NT-proBNP market. Reimbursement challenges limit the adoption of BNP and NT-proBNP testing by creating uncertainty around coverage, pricing and claim approvals across payers. When reimbursement rates are low or inconsistent, hospitals and laboratories may hesitate to expand routine cardiac biomarker testing. Complex billing codes and documentation requirements also slow test utilization and delay payments. This financial uncertainty reduces testing frequency and restricts broader clinical integration. Growth affected by the reimbursement challenges during the forecast period in 2025 is -1.0%. • Lack Of Standardization In Testing (Medium) – During the forecast period, lack of standardization in testing is restricting the growth of the BNP and NT-proBNP market. Lack of standardization in BNP and NT-proBNP testing restricts market growth because results can vary across assay platforms, laboratories and measurement methods, reducing clinical comparability. Different calibration systems and cutoff values make it difficult for physicians to interpret results consistently across care settings. This variability limits guideline harmonization and slows broader adoption in routine screening and monitoring. It also increases the risk of misclassification of heart failure severity, lowering clinician confidence in cross-lab data. As a result, procurement and integration into unified diagnostic pathways become more challenging. Growth affected by the lack of standardization in testing during the forecast period in 2025 is -0.5%. • Impact Of Trade Wars And Tariffs (Low) – During the forecast period, the impact of trade wars and tariffs is restricting the growth of the BNP and NT-proBNP market. Trade wars and cross-border tariff barriers can hinder the BNP and NT-proBNP diagnostics market by increasing the cost of imported reagents, assay kits and analyzer components. Higher duties on medical devices and raw materials disrupt global supply chains and delay product availability for laboratories and hospitals. Regulatory friction and trade restrictions also slow international collaborations and technology transfer in cardiac biomarker testing. Currency volatility linked to trade conflicts further raises procurement costs for diagnostic providers. Together, these factors can restrict market expansion and reduce testing accessibility in price-sensitive regions. Growth affected by the impact of trade wars and tariffs during the forecast period in 2025 is -0.3%.

Key Players In The Global BNP And NTproBNP Market

Major companies operating in the bnp and ntprobnp market are Abbott Laboratories, Gentian Diagnostics ASA, Siemens AG, PerkinElmer Inc., Biomerieux SA, Quidel Corporation, Bio-Rad Laboratories Inc., F Hoffman La Roche Ltd., CTK Biotech Inc., RayBiotech Life Inc., BHR Pharmaceuticals Ltd., Getein Biotech Inc., VACURE Biotechnology Co. Ltd., Bio-Techne Co., Xiamen Biotime Biotechnology Co. Ltd., Scripps Laboratories Inc., Danaher Corporation, Beckman Coulter Inc., Thermo Fisher Scientific Inc., Randox Laboratories Ltd., LSI Medience Corporation, Shionogi & Co. Ltd., Radiometer Medical ApS, Ortho Clinical Diagnostics, Tosoh Corporation, Aidian Oy, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Becton Dickinson and Company, Acon Laboratories Inc., Response Biomedical Corp., Nanomix Inc., Cepheid Inc., Alere Inc.

Global BNP And NTproBNP Market Trends and Insights

Major companies operating in the BNP and NTproBNP market are increasing their focus on introducing rapid screening bioassays to gain a competitive edge in the market. Rapid screening bioassays refer to biological tests that efficiently assess the presence, concentration, or activity of a substance by measuring its effects on living cells or organisms, enabling quick and reliable identification or categorization of specific attributes or conditions. For instance, in October 2023, Mindray Medical International Limited, a China-based medical device company, launched two new assays that can help diagnose and manage cardiovascular diseases (CVDs). These assays are called high-sensitivity troponin I (hs-cTnI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP). By adding these new assays to its diverse portfolio of cardiac biomarkers, Mindray has enhanced its ability to screen, stratify risk, diagnose rapidly, and monitor therapy for CVDs. Mindray collaborated with HyTest, a pioneer in cardiac biomarkers, to integrate HyTest's research and antibodies into Mindray's immunoassay platforms.

What Are Latest Mergers And Acquisitions In The BNP And NTproBNP Market?

In July 2024, Roche Holding AG, a Switzerland-based company specializing in pharmaceuticals and diagnostics, acquired LumiraDx Limited for an undisclosed amount. This acquisition aims to enhance Roche's diagnostics portfolio by integrating innovative point-of-care technology that enables rapid testing for BNP and NT-proBNP. LumiraDx Limited is a UK-based diagnostics company recognized for innovative rapid test for NT-proBNP.

What Defines the BNP And NTproBNP Market?

The BNP and NTproBNP market includes revenues earned by companies by providing diagnostic and heart disease detection services using BNP (B-type natriuretic peptide) or NT-proBNP (N-terminal Pro-brain Natriuretic Peptide) as biomarkers, BNP and NTproBNP assays. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the BNP And NTproBNP Market Report 2026?

The bnp and ntprobnp market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the bnp and ntprobnp industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.